BayCom (BCML) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for June 16, 2026, with shareholders voting on director elections, executive compensation, and auditor ratification.
A major leadership transition occurred in April 2026, with new executive appointments and the departure of the prior CEO, COO, and CFO, who will provide transition support until July 6, 2026.
The new executive team brings experience in balance sheet growth, capital markets, and transformational transactions, aiming to enhance earnings and pursue strategic combinations.
Voting matters and shareholder proposals
Shareholders will vote on electing nine directors for one-year terms, an advisory say-on-pay vote, and ratification of Baker Tilly as the independent auditor for 2026.
Shareholder nominations for directors must follow specific advance notice and information requirements.
The board recommends voting FOR all proposals.
Board of directors and corporate governance
The board consists of nine members with diverse backgrounds in law, banking, finance, real estate, and community service.
Seven directors are deemed independent under NASDAQ rules.
The board separates the roles of CEO and Chairman and emphasizes ethics, diversity, and community engagement.
Committees include Audit, Compensation, and Corporate Governance/Nominating, each with formal charters and independent membership.
Latest events from BayCom
- Q1 2026 net income surged 43.5% to $8.2M, with improved margins, asset growth, and new leadership.BCML
Q1 202611 May 2026 - Annual meeting to elect directors, vote on pay, and ratify auditor, with online voting available.BCML
Proxy filing29 Apr 2026 - Q4 2025 earnings grew 37% sequentially on higher net interest income and lower credit loss provisions.BCML
Q4 202522 Jan 2026 - Director elections, say-on-pay, and auditor ratification headline a governance-focused agenda.BCML
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor, with online proxy access.BCML
Proxy Filing2 Dec 2025 - Earnings declined on higher credit loss provisions, but capital and liquidity remain strong.BCML
Q3 20257 Nov 2025 - Q2 2024 net income fell 22% as margins compressed, but capital and deposits remained strong.BCML
Q2 202414 Oct 2025 - Earnings and net interest margin improved, with robust capital and higher nonperforming loans.BCML
Q2 202511 Aug 2025 - Q3 net loss widened to $16.8M; $182.2M cash on hand supports clinical pipeline into 2027.BCML
Q3 202413 Jun 2025